Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Clinical Genomics Laboratory, |
RCV005251037 | SCV005902169 | likely pathogenic | PIK3CA related overgrowth syndrome | 2024-09-09 | criteria provided, single submitter | clinical testing | A PIK3CA c.1636C>G (p.Gln546Glu) variant was identified at an allelic fraction consistent with somatic origin. This variant has been reported in a patient with overgrowth and capillary malformation (Mojarad B et al., 2023) as well as in numerous cases in the cancer database COSMIC (COSV55882350). It is absent from the general population (gnomAD v.4.1.0), indicating it is not a common variant. The PIK3CA c.1636C>G (p.Gln546Glu) variant resides within the helical domain of the protein and other variants at the same codon, p.Gln546Lys, p.Gln546Leu, p.Gln546Pro, p.Gln546Arg, p.Gln546His, have been reported and are considered likely pathogenic or pathogenic (ClinVar ID's: 13657, 375899, 375898, 45466, 376491). Functional studies show increased cell survival and transforming ability in culture, indicating that this variant impacts protein function (Dogruluk T et al., PMID: 26627007;Ng PK et al, PMID: 29533785). The PIK3CA gene is defined by the ClinGen Brain Malformations expert panel as a gene that has a low rate of benign missense variation and where pathogenic missense variants are a common mechanism of disease.Based on available information and an internally developed protocol informed by the ACMG/AMP guidelines for variant interpretation and gene-specific practices from the ClinGen Criteria Specification Registry (Leon-Quintero FZ et al., PMID: 39434542), the PIK3CA c.1636C>G (p.Gln546Glu) variant is classified as likely pathogenic. |
| OMIM | RCV000014630 | SCV000034885 | pathogenic | Breast adenocarcinoma | 2004-11-01 | no assertion criteria provided | literature only |